grant
Validation of biomarkers for risk prediction and early diagnosis of Pancreatic Adenocarcinoma
Organization UNIVERSITY OF PITTSBURGH AT PITTSBURGHLocation PITTSBURGH, UNITED STATESPosted 17 May 2016Deadline 31 Mar 2028
NIHUS FederalResearch GrantFY2025AbscissionAccountingAntigenic DeterminantsArchivesAutoantibodiesBinding DeterminantsBiological MarkersBlindedBloodBlood Reticuloendothelial SystemBlood SampleBlood SerumBlood VesselsBlood specimenCA-19-9CA-19-9 AntigenCA19-9Cancer Antigen 19-9Cancer CauseCancer EtiologyCancersCarbohydrate Antigen 19-9Case-Base StudiesCase-Comparison StudiesCase-Compeer StudiesCase-Referent StudiesCase-Referrent StudiesCase/Control StudiesCessation of lifeClinicalConsensusCystCyst FluidCystic LesionDNA mutationDeathDevelopmentDiabetes MellitusDiagnosisDiseaseDisorderDistantDysplasiaEarly DiagnosisEpitopesEvaluationExcisionExtirpationFamilial pancreatic cancerFamilyFamily Medical HistoryFamily Medical History EpidemiologyFamily history ofFundingGastrointestinal Cancer AntigenGeneral PopulationGeneral PublicGeneticGenetic ChangeGenetic defectGenetic mutationGerm-Line MutationGoalsGuidelinesHereditaryHereditary MutationHistoryIndividualInheritedLaboratoriesLesionLocalized DiseaseMUC5ACMUC5AC geneMalignantMalignant - descriptorMalignant NeoplasmsMalignant Pancreatic NeoplasmMalignant TumorMalignant neoplasm of pancreasMedical centerMinorityMorbidityMorbidity - disease rateMucinousMucinsMucus GlycoproteinMutationNatureNeoplasmsNewly DiagnosedOperative ProceduresOperative Surgical ProceduresOrganPancreasPancreas AdenocarcinomaPancreas CancerPancreas CystPancreaticPancreatic AdenocarcinomaPancreatic CancerPancreatic CystPancreatic DiseasesPancreatic DisorderPancreatic cystic neoplasiaPatientsPerformancePersonsPhasePopulationPredicting RiskPredispositionProspective StudiesRecording of previous eventsRemovalReportingResectableResectedRetrospective StudiesRiskSamplingSerumSialyl Lewis (A) AntigenSpecificitySurgicalSurgical InterventionsSurgical ProcedureSurgical RemovalSurvival RateSusceptibilityTIMP2TIMP2 geneUnited Statesautoimmune antibodyautoreactive antibodybio-markersbiologic markerbiomarkerbiomarker arraybiomarker panelbiomarker performancebiomarker utilitybiomarker validationblood-based biomarkerblood-based markercandidate biomarkercandidate markercandidate validationcase controlcase-controlledcase-controlled studieschronic pancreatitisclinical validationcohortdeath riskdevelopmentaldiabetesdiagnostic biomarkerdiagnostic markerdisease causing variantdisease-causing alleledisease-causing mutationdraining lymph nodedyscrasiaearly biomarkersearly detectionearly detection biomarkersearly detection markersforecasting riskgenome mutationgerm-line defectgermline varianthereditary pancreatic cancerhigh riskhigh risk grouphigh risk individualhigh risk peoplehigh risk populationhistoriesimprovedinflammation markerinflammatory markermalignancymarker panelmarker validationmortality riskneoplasianeoplasm/cancerneoplastic growthnovelpancreas disorderpancreatic cystic lesionspancreatic cystic neoplasmspancreatic cystic tumorspancreatic malignancypathogenic allelepathogenic variantpatient subclasspatient subclusterpatient subgroupspatient subpopulationspatient subsetspatient subtypespredict riskpredict riskspredicted riskpredicted riskspredicting riskspredictive riskpredicts riskprospectiverecurrent pancreatitisregional lymph noderesectionrisk predictionrisk predictionsrisk stratificationsample collectionscreeningscreeningsself reactive antibodyspecimen collectionstratify risksurgerysurveillance imagingsurveillance strategytumorvalidation studiesvascular
Description preview
Abstract
Pancreatic adenocarcinoma (PDAC), with an overall 5-year survival of 11%, is the 3rd most common
cause of cancer deaths in the United States, despite accounting for only 2% of all malignancies. Only a minority
of patients (~11%) are diagnosed with “localized” disease (I or IIA), which has a 5-year survival rate of about
40% in setting of…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click